{"url_path":"/sec/mira/8-k/2026-05-13/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1904286/0001493152-26-022608-index.html","accession_number":"0001493152-26-022608","cik":"0001904286","ticker":"MIRA","issuer_name":"MIRA PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1904286/0001493152-26-022608-index.html","primary_entity_key":"0001904286","primary_entity_name":"MIRA PHARMACEUTICALS, INC."},"word_count":304,"has_tables":true,"body_markdown":"false\n0001904286\n\n0001904286\n\n2026-05-12\n2026-05-12\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**WASHINGTON,\nD.C. 20549**\n\n \n\n**FORM\n8-K**\n\n \n\n**CURRENT\nREPORT**\n\n \n\n**Pursuant\nto Section 13 or 15(d) of the**\n\n**Securities\nExchange Act of 1934**\n\n \n\nDate\nof Report: **May 12, 2026**\n\n \n\n \n\n \n\n**MIRA\nPHARMACEUTICALS, INC.**\n\n(Exact\nName of Registrant as Specified in its Charter)\n\n \n\n \n\n \n\n**Florida**\n \n**001-41765**\n \n**85-3354547**\n\n(State\nor Other Jurisdiction\n \n(Commission\n \n(IRS\nEmployer\n\nof\nIncorporation)\n \nFile\nNumber)\n \nIdentification\nNo.)\n\n \n\n**1200\nBrickell Avenue, Suite 1950 #1183**\n\n**Miami, Florida 33131**\n\n(Address of Principal Executive Offices)\n\n \n\n**(786) 432-9792**\n\n(Registrant’s\ntelephone\n\nnumber,\nincluding area code)\n\n \n\n \n\n(Former\nName or Former Address, if Changed Since Last Report)\n\n \n\nCheck\nthe appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under\nany of the following provisions:\n\n \n\n☐\nWritten communications pursuant to Rule 425 under the Securities\nAct (17 CFR 230.425)\n\n \n \n\n☐\nSoliciting material pursuant to Rule 14a-12 under the Exchange\nAct (17 CFR 240.14a-12)\n\n \n \n\n☐\nPre-commencement communications pursuant to Rule 14d-2(b) under\nthe Exchange Act (17 CFR 240.14d-2(b))\n\n \n \n\n☐\nPre-commencement communications pursuant to Rule 13e-4(c) under\nthe Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:\n\n \n\nTitle\nof each class\n \nTrading\nSymbol\n \nName\nof each exchange on which registered\n\nCommon\nStock, $0.0001 par value per share\n \nMIRA\n \nThe\nNasdaq Capital Market\n\n \n\nIndicate\nby check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405\nof this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging\ngrowth company ☒\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐"}